Crystal structure of tramadol hydrochloride, C16H26NO2Cl

被引:4
|
作者
Kaduk, James A. [1 ]
Zhong, Kai [2 ]
Gindhart, Amy M. [2 ]
Blanton, Thomas N. [2 ]
机构
[1] IIT, 3101 S Dearborn St, Chicago, IL 60616 USA
[2] ICDD, Newtown Sq, PA 19073 USA
关键词
tramadol hydrochloride; Ultram; powder diffraction; Rietveld refinement; density functional theory; AB-INITIO; VALIDATION; PATTERNS; DENSITY;
D O I
10.1017/S088571561500041X
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
The crystal structure of tramadol hydrochloride has been solved and refined using synchrotron X-ray powder diffraction data, and optimized using density functional techniques. Tramadol hydrochloride crystallizes in space group Cc (#9) with a = 9.680 72(2), b = 19.191 27(4), c = 9.285 94(1)angstrom, beta = 100.5923(1)degrees, V = 1695.795(5)angstrom(3), and Z = 4. The solid-state conformation of the cation differs from the minimum-energy conformation of the tramadol cation in water, and from the conformation observed in the benzoic acid adduct of tramadol hydrochloride. N-H center dot center dot center dot Cl and O-H center dot center dot center dot Cl hydrogen bonds form a zigzag chain with graph set C1,2(8) along the c-axis. C-H center dot center dot center dot O hydrogen bonds also contribute to the crystal energy. The powder pattern has been submitted to ICDD for inclusion in the Powder Diffraction File T. (C) 2015 International Centre for Diffraction Data.
引用
收藏
页码:242 / 249
页数:8
相关论文
共 50 条
  • [1] Crystal structure of terazosin hydrochloride dihydrate (Hytrin®), C19H26N5O4Cl(H2O)2
    Wheatley, Austin M.
    Kaduk, James A.
    Vickers, Martin
    Gindhart, Amy M.
    Sunzeri, Joseph G.
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2018, 33 (03) : 229 - 236
  • [2] Crystal structure of alfuzosin hydrochloride, C19H28N5O4Cl
    Kaduk, James A.
    POWDER DIFFRACTION, 2022, 37 (03) : 171 - 182
  • [3] Crystal structure of ziprasidone hydrochloride monohydrate, C21H22Cl2N4OS(H2O)
    Kaduk, James A.
    Zhong, Kai
    Gindhart, Amy M.
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2015, 30 (03) : 192 - 198
  • [4] Crystal structure of fingolimod hydrochloride, C19H34ClNO2
    Kaduk, James A.
    Zhong, Kai
    Gindhart, Amy M.
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2015, 30 (03) : 205 - 210
  • [5] Crystal structure of diclazuril, C17H9Cl3N4O2
    Kaduk, James A.
    Gates-Rector, Stacy
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2022, 37 (04) : 230 - 234
  • [6] Crystal structure of baricitinib, C16H17N7O2S
    Lee, Yewon
    Wang, Yulong
    Khalifah, Peter G.
    Stephens, Peter W.
    Kaduk, James A.
    Gates-Rector, Stacy
    Gindhart, Amy M.
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2022, 37 (03) : 150 - 156
  • [7] Crystal structure of levalbuterol hydrochloride polymorph A (Xopenex), C13H22NO3Cl
    Kaduk, James A.
    Zhong, Kai
    Blanton, Thomas N.
    Gates, Stacy
    POWDER DIFFRACTION, 2015, 30 (02) : 158 - 162
  • [8] Crystal structure of etrasimod, C26H26F3NO3
    Kaduk, James A.
    Dosen, Anja
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2025,
  • [9] Crystal structure of ractopamine hydrochloride, C18H24NO3Cl
    Scherry, Colin W.
    Boaz, Nicholas C.
    Kaduk, James A.
    Dosen, Anja
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2024, 39 (02) : 94 - 104
  • [10] Crystal structure of mupirocin form I, C26H44O9
    Kaduk, James A.
    Zhong, Kai
    Gindhart, Amy M.
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2016, 31 (02) : 118 - 125